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thoracoscopy (MT)Dear Editor,
As well as reducing delays for patients waiting for depart-
mental thoracic ultrasound (TUS) for pleural procedures as
reported by Bateman et al.,1 chest physician-operated
decubitus thoracic ultrasound (TUS) prior to medical thor-
acoscopy (MT) when an artificial pneumothorax technique
is not introduced may have additional benefits which have
been reported in two studies.2,3 This has recently been
utilised in one institution and reduced pleural access failure
(defined as inability to aspirate pleural fluid) rate from
16.7% to zero in two series of 30 patients undergoing single
port MT without an artificial pneumothorax.4 This has pre-
vented patients having to undergo further procedures.
Not all centres use chest physician-operated TUS. The
greatest barrier to this is cost. A basic portable TUS
machine costs between £13,500e22,000 depending on
technical specification. Some cost reductions can be ach-
ieved using charitable funds, ex-demonstration models and
local negotiation but it is key to demonstrate cost benefits
of TUS.
In the MT cohort of 30 patients without TUS,4 5 patients
required extra investigations (as pleural access was not
possible) leading to further costs to the commissioners: 3
CT-guided pleural biopsies (CTBx) and 2 video-assisted
thoracoscopic surgery (VATS) pleural biopsies. On average,
60 patients undergo MT in our institution annually, extrap-
olating to 6 CTBx and 4 VATS procedures. From the 2009/10
National Tariffs, this would result in an extra cost to the
commissioners of £14972.5 It is therefore estimated that in
1e1.5 years, sufficient cost savings to the commissioner
could be generated to cover the cost of a basic portable TUS
machine.
The limitations of this extrapolated analysis are
acknowledged. It relates to single port MT without creating
an artificial pneumothorax and may not relate to other
variations of MT. Failure to enter the pleural cavity in the
initial TUS cohort4 can sometimes be anticipated on the CTDOI of original article: 10.1016/j.rmed.2009.12.014.
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doi:10.1016/j.rmed.2010.03.004scan showing loss of volume, pachypleuritis or calcification
and similar rates of pleural access failure may not be
replicated in other studies. In other centres, radiology may
deliver all TUS services but in centres where radiology
capacity is more limited, then chest physician-operated
TUS may be helpful. Finally, it is acknowledged that this
theoretical reduction would require validation in studies of
chest physician-operated TUS.
The potential cost benefits of TUS have been deliber-
ately underestimated and the additional benefits already
described by Bateman et al.1 of reducing the time to
diagnosis for inpatients have not been included (avoiding
waits for radiology-operated TUS) and reduced length of
stay: a reduction of just one hospital day for 150 patients
with pleural effusion over a year would lead to an actual
cost reduction of approximately £34,050 (£227 per night
stay, UHL Trust Corporate Management Accountant
Department, personal communication). Other potential
cost savings not included are TUS-guided supraclavicular
node aspiration (of impalpable nodes) in reducing lung
cancer diagnosis waiting time, avoidance of other more
invasive investigations and reducing time to treatment.6
Despite all the above limitations, in summary it is
possible to generate a plausible business case for acquisi-
tion of portable TUS for all respiratory centres encoun-
tering patients with pleural effusion especially those using
single port MT. Successful acquisition of portable TUS will
improve the quality of care and safety for patients under-
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